CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- 4 Open-market buy CEO and CFO bought 6,774 shares at $7.38 ($49,992)
- 4 Open-market buy Chief Medical Officer bought 1,000 shares at $16.25 ($16,250)
- 4 Open-market buy CEO and CFO bought 6,000 shares at $16.09 ($96,540)
- 4 Open-market buy CEO and CFO bought 6,000 shares at $16.74 ($100,440)
- 4 Open-market buy VP Clinical Reg Affairs bought 500 shares at $16.74 ($8,370)
- 4 Open-market buy CEO and CFO bought 5,500 shares at $19.80 ($108,900)
- 4 Open-market buy CEO and CFO bought 5,000 shares at $19.59 ($97,950)
- 4 Open-market buy VP Clinical Reg Affairs bought 500 shares at $18.47 ($9,235)
- 4 Open-market buy VP Clinical Reg Affairs bought 500 shares at $16.33 ($8,165)
- 4 Open-market buy Director bought 300 shares at $16.32 ($4,896)
- 4 Open-market buy VP Clinical Reg. Affairs bought 500 shares at $18.87 ($9,435)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $19.99 ($19,990)
- 4 Open-market buy VP Clinical Reg. Affairs bought 1,000 shares at $19.99 ($19,990)
- 4 Open-market buy Chief Medical Officer bought 1,000 shares at $19.99 ($19,990)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy CEO and CFO bought 2,050 shares at $23.82 ($48,831)
- 4 Open-market buy CEO and CFO bought 1,840 shares at $27.17 ($49,992)
- 4 Open-market buy Chief Medical Officer bought 1,111 shares at $26.99 ($29,983)
- 4 Open-market buy Director bought 200 shares at $27.56 ($5,512)
- 4 Open-market buy CEO and CFO bought 2,700 shares at $36.98 ($99,853)
Page 6 of 8 · 146 filings